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and benchmarking both internally and externally, an 
assessment and determination of satisfaction has been 
possible. 
Materials and Methods: The standard AIR staffing model 
(from 2001) which is routinely utilised in Australia states a 
requirement of 4.5 FTE on a Linear Accelerator treating 
around 40 patients per day. Following a workflow redesign, 
ROV implemented a staffing model of 3.0FTE for a similar 
workload on its Linear Accelerator fleet. After this change, 
patient satisfaction with the service was assessed by 
obtaining patient satisfaction scores using an iPad device 
connected to cloud based software using a net promoter 
score methodology. The recorded scores of satisfaction were 
compared to both internal and external controls and 
demonstrated that changes to the staffing model had no 
impact on the quality of service provided.  
Results: After 13 months of data collection involving 1688 
patients across 5 sites, the NPS data analysis demonstrates a 
consistent score of at least 70% (noting a NPS score of >40% is 
considered very good).  
Conclusions: The data demonstrates that the new staffing 
model adopted by ROV maintains excellent levels of service 
as evidenced by patient satisfaction. ROV continues to 
monitor patient satisfaction on an ongoing basis to ensure the 
service provided continues to meet or exceed expectations. 
In the event that a respondent is dissatisfied by a score on 
any metric of less than 60%, contact with the respondent is 
made immediately as the cloud based system provides real 
time notification to a manager. 
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Purpose/Objective: Comorbidity assessment is essential to 
triage of care for men with prostate cancer. Specially in 
these with an expectative of life less of ten yars.. We tried to 
make a Spanish validation of revised Charlson index (RCI) 
applied to prostate cancer. 
Materials and Methods: A group of 619 consecutive cases of 
prostate cancer diagnosed between 1994 to 2007 weresend 
for clinical assessment at radiation oncology department of 
hospital Clinic of Bacelona. A long the period of follow-up 69 
patients deceased for prostate cancer and were excluded in 
this study inorder to determine the risks of mortality 
associated with comorbidities measured by the RCI. RCI was 
classified in three categories 0 to 2 , 3 to 4 and 5 and higher. 
For this purpose we used Kaplan-Meier method and Cox 
proportional hazards modeling . 
Results: Finally 550 patients with prostate cancer were 
included, with median age of 70 years old (47-85), Mean 
follow-up time was 136.8 months, between 5,6 and 245,8 
months. D’Amico risk classification distribution was for low, 
mediun and high risk 20.4%, 36,5% and 43,1% respectively. 
RCI distribution categories was as follows 61,5%, 21,8 and 
16,7%. Survival analysis showed significant differences 
(p<0.001) between RCI groups at 5 and 10 years. Survival 
probability was 98,2 and 88,5% ; 95% and 79,6% ; and 52,2% 
and 8,9% respectively for each RCI category.  
Conclusions: RCI allowed for more accurate identification of 
men at highest risk for other cause mortality. Our results are 
in concordance with original RCI .This revised index may be 
used to aid medical decision making for men with prostate 
cancer. 
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Purpose/Objective: Short-course radiotherapy (SCRT) 
followed by immediate surgery at 1 week is an option 
treatment in rectal cancer, and it is generally accepted that 
SCRT is associated with less early toxicity than conventionally 
fractionated chemoradiotherapy. Currently, the SCRT and 
delayed surgery (i.e. 4–8 weeks) after radiotherapy (RT) is 
being evaluated in order to improve results. It seems that 
longer surgery delays are associated with a better tumor 
response, but acute toxicity has not been evaluated 
accurately. Our aim was to evaluate the acute toxicity of 
patients treated with SCRT in the weeks before the surgery in 
our hospital.  
Materials and Methods: 17 patients with localized rectal 
cancer staged T3-4N0/+ treated with 25 Gy in 5 consecutive 
fractions followed by surgery were analyzed. All patients 
received 3D conformal RT with a multileaf collimator (MLC) 
and were immobilized in the supine position. The CTV 
included the rectum, mesorectum, common and internal iliac 
vessels with a 1-cm margin, presacral space, posterior part of 
the internal obturator muscle and 1–2 cm of the bladder. 
Surgery was performed 1-3 weeks after the beginning of RT. 
Surgery was performed 1 week after RT in 6 patients, 2 
weeks after RT in 9 patients, and after 3 weeks in 2 patients. 
Acute toxicity assessment was performed during routine 
follow-up examinations and toxicity grades were assessed 
with the RTOG scale. All data analyzed by Microsoft Office 
Excel 2007. 
Results: Little toxicity was observed in the 6 patients in 
whom the surgery was performed 1 week after RT: asthenia 
(grade 1), proctitis (grade 1) and cystitis (grade 1-2). No 
other types of acute toxicity were observed. Patients in 
whom surgery was delayed 2-3 weeks after RT, acute toxicity 
get worse (≥ grade 2-3). (Figure 1)The most severe symptoms 
were asthenia, diarrhea and proctitis. Urinary incontinence 
was maintained equal. 2 patients that had surgery beyond 3 
weeks from the end of RT required admission for symptom 
control. In all cases, surgery delay was due to surgical 
waiting list. 
3rd ESTRO Forum 2015                                                                                                                                         S919 
 
 
 
 
 
Conclusions: Our data suggest that SCRT followed by delayed 
surgery (1 week) is well tolerated. However, beyond the 2-3 
week toxicity increases and may require medical treatment 
at the hospital. SCRT and delayed surgery (4-8 weeks after 
radiotherapy) may improve outcomes, but the acute toxicity 
of these patients should be carefully evaluated. 
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Purpose/Objective: Skin reactions from external beam 
radiotherapy are one of the most common side-effects from 
treatment (1, 2), and may cause distress to some patients, 
and in certain cases may be a factor which can limit radiation 
dose and treatment schedules. Megavoltage linear 
accelerators with skin sparing capabilities have significantly 
reduced the severity of reactions from radiotherapy; however 
accelerated radiation dose schedules with concurrent 
chemotherapy, and the use of biological agents such as 
epidermal growth factor receptor (EGFR) inhibitors, have led 
to an increase in certain skin reactions (3). Significant skin 
reactions are also seen in patients receiving high doses to 
large fields, in patients where there are folds of skin (for 
example inframmary fold, groin, axilla) and patients 
receiving radiotherapy to the head and neck region (4, 5). 
Yet despite changes in radiotherapy practice and numerous 
published skin care guidelines (6, 7)) patient skin care 
appears to have changed little over the years, with no 
consensus amongst centres using different skin care 
regimens, product use and approaches. 
Materials and Methods: A Guideline Development Group have 
reviewed the current evidence to assist radiographers, 
radiotherapy nurses, and the wider radiotherapy workforce, 
to give the optimal skin care advice to patients undergoing 
radical external beam megavoltage radiotherapy. Although it 
is unlikely that radiation reactions can be completely 
prevented, the current driver is to delay the onset and 
minimise the severity of a skin reaction, to reduce symptom 
related discomfort, and prevent further complications. 
Results: The recommendation from the guidance document is 
to standardise skin care education of all staff caring for 
patients receiving radiotherapy by dissemination of the 
guidance using a variety of educational methods. 
Conclusions: Standardise assessment tools across 
departments which are objective and consistent. Consider 
the evidence on current products and start new high quality 
trials to investigate interventions for dry or moist 
desquamation enabling a more consistent approach for 
patients receiving radiotherapy and inform radiotherapy skin 
care guidelines. 
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Purpose/Objective: Given that radiotherapy is usually an 
outpatient treatment, the nurse has to provide the patient 
and the carer the necessary information and support to 
resolve the process positively and to jointly elaborate a plan 
for cures adapted to the various situations, which the patient 
will be undergoing.  
The carer is usually someone from the family, a neighbour or 
a friend without specific training, who will become key to the 
link between the patient and the nurse. 
In this paper, we would like to measure the degree of 
satisfaction of the task of the carer during the treatment and 
also to receive feedback for the response they have received 
from the nurse. 
To improve the healing of the patient. 
 To detect early problems encountered related to 
the patient's illness. 
